Azitra (AZTR) Accounts Payables (2022 - 2026)
Azitra (AZTR) posted Accounts Payables of $932217.0 for Q1 2026, up 133.43% on a QoQ basis from $399356.0 in Q4 2025, and up 66.79% year-over-year from $558924.0 in Q1 2025.
Azitra (AZTR) Accounts Payables (2022 - 2026) Analysis & Trends
Azitra's Accounts Payables history runs 5 years deep, the most recent figure standing at $932217.0 for Q1 2026.
- Quarterly Accounts Payables rose 66.79% year-over-year to $932217.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $932217.0 (up 66.79% YoY) and the FY2025 annual result came in at $399356.0, down 18.54% from the prior year.
- Accounts Payables was $932217.0 for Q1 2026 at Azitra, up from $399356.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $996700.0 in Q2 2024 and bottomed at $364183.0 in Q2 2023.
- A 5-year average of $643642.7 and a median of $588460.0 in 2024 frame the typical range for Accounts Payables.
- Peak annual rise in Accounts Payables reached 173.68% in 2024, while the deepest fall reached 45.36% in 2024.
- Azitra's Accounts Payables stood at $784687.0 in 2022, then climbed by 14.35% to $897272.0 in 2023, then sank by 45.36% to $490255.0 in 2024, then decreased by 18.54% to $399356.0 in 2025, then surged by 133.43% to $932217.0 in 2026.
- Business Quant data shows AZTR's Accounts Payables at $932217.0 in Q1 2026, $399356.0 in Q4 2025, and $718476.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | 10.38 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 8.64 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 423.55 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 489.30 Mn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 1.03 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 1.52 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 126.63 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 80.54 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 932,217.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 932,217.00 |
| Dec 31, 2025 | 399,356.00 |
| Sep 30, 2025 | 718,476.00 |
| Jun 30, 2025 | 635,842.00 |
| Mar 31, 2025 | 558,924.00 |
| Dec 31, 2024 | 490,255.00 |
| Sep 30, 2024 | 588,460.00 |
| Jun 30, 2024 | 996,700.00 |
| Mar 31, 2024 | 583,055.00 |
| Dec 31, 2023 | 897,272.00 |
| Sep 30, 2023 | 417,928.00 |
| Jun 30, 2023 | 364,183.00 |
| Dec 31, 2022 | 784,687.00 |